Record CGuard Revenue
CGuard revenue reached a new quarterly high of $1.95 million in Q4 2024, reflecting a 10.6% growth year-over-year, with $7 million in revenue for the full year 2024, translating to 13% growth compared to 2023.
CGuard Prime US Market Entry
Anticipated US approval and launch of CGuard Prime in the first half of 2025, with potential revenue of over $16 million if Q4 sales were in the US market.
Strong Clinical Trial Results
CGUARDIANS trial results showed a major adverse events rate of just 0.95% through 30 days and 1.95% through 12 months post-procedure, the lowest ever reported in a pivotal study of carotid stent or embolic protection device.
Strategic US Headquarters
New headquarters in Miami, Florida, to support the anticipated US launch and commercialization of CGuard Prime.